RGX-314 Gene Therapy Study for Wet AMD: This study aims to test a new one-time gene therapy called RGX-314 for treating wet Age-related Macular Degeneration (AMD), a condition that causes vision loss due to leaky blood vessels in the eye. Current treatments involve frequent eye injections, but RGX-314 might offer a long-lasting solution with just one treatment. This is a Phase 3 clinical trial, meaning it’s in a late stage of testing to check how well it works and its safety. Participants will be randomly assigned to receive RGX-314 at different doses or a comparison treatment. Researchers will focus on changes in vision clarity. To join, you must be between 50 and 89 years old, have been previously treated for wet AMD, and meet other specific health criteria. The study involves around 465 participants.

• Study Duration: Participation involves multiple visits over time.
• Eligibility: Specific age and health conditions apply.
• Potential Risks: As with any study, there may be risks involved.